Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q36470627)
Watch
English
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
title
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
(English)
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
main subject
prostate cancer
1 reference
based on heuristic
inferred from title
author
Daniel Crona
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
Young Whang
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
author name string
M I Milowsky
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
language of work or name
English
0 references
publication date
1 October 2015
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
published in
Clinical Pharmacology & Therapeutics
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
volume
98
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
issue
6
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
page(s)
582-589
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
cites work
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Androgen receptor aberrations in the era of abiraterone and enzalutamide
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Cancer statistics, 2015
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Constitutive activity of the androgen receptor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Enzalutamide in metastatic prostate cancer before chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Alpha emitter radium-223 and survival in metastatic prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
An androgen receptor N-terminal domain antagonist for treating prostate cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Overcoming mutation-based resistance to antiandrogens with rational drug design
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Abiraterone in metastatic prostate cancer without previous chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Progress in emerging therapies for advanced prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Increased survival with enzalutamide in prostate cancer after chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
ARN-509: a novel antiandrogen for prostate cancer treatment
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Abiraterone and increased survival in metastatic prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Development of a second-generation antiandrogen for treatment of advanced prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Molecular determinants of resistance to antiandrogen therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Molecular biology of the androgen receptor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
The current state of hormonal therapy for prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
The development of androgen-independent prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
30 September 2017
Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
28 June 2018
Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
28 June 2018
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
28 June 2018
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
28 June 2018
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
28 June 2018
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
28 June 2018
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
21 September 2018
Galeterone activity in castration-resistant prostate cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
21 September 2018
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
21 September 2018
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
21 September 2018
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
21 September 2018
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4715745
retrieved
21 September 2018
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCPT.256
retrieved
21 January 2018
Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCPT.256
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Stepwise androgen receptor dimerization
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCPT.256
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCPT.256
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/26331358
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1002/CPT.256
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
PMCID
4715745
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
PubMed ID
26331358
1 reference
stated in
Europe PubMed Central
PMCID
4715745
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26331358%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
